BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

Stock Information for Citius Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Citius Pharmaceuticals Inc.

BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation
BriaCell Therapeutics Announces Closing of US$30 million Public Offering
BriaCell Therapeutics Announces Pricing of $30 million Public Offering
BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS(TM) Patient
How $594B in Precision Tech is Cracking the Metastatic Cancer Code
"Eleven clinical trials that will shape medicine in 2026" - BriaCell Phase 3 Trial Featured in Nature Medicine
BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025
BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.